Literature DB >> 17628203

Prodrug strategies to overcome poor water solubility.

Valentino J Stella1, Kwame W Nti-Addae.   

Abstract

Drug design in recent years has attempted to explore new chemical spaces resulting in more complex, larger molecular weight molecules, often with limited water solubility. To deliver molecules with these properties, pharmaceutical scientists have explored many different techniques. An older but time-tested strategy is the design of bioreversible, more water-soluble derivatives of the problematic molecule, or prodrugs. This review explores the use of prodrugs to effect improved oral and parenteral delivery of poorly water-soluble problematic drugs, using both marketed as well as investigational prodrugs as examples. Prodrug interventions should be considered early in the drug discovery paradigm rather than as a technique of last resort. Their importance is supported by the increasing percentage of approved new drug entities that are, in fact, prodrugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628203     DOI: 10.1016/j.addr.2007.05.013

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  69 in total

Review 1.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

Review 2.  Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges.

Authors:  Hong Wen; Huijeong Jung; Xuhong Li
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

3.  Ribonuclease-Activated Cancer Prodrug.

Authors:  Gregory A Ellis; Nicholas A McGrath; Michael J Palte; Ronald T Raines
Journal:  ACS Med Chem Lett       Date:  2012-02-28       Impact factor: 4.345

4.  Computationally designed prodrugs of statins based on Kirby's enzyme model.

Authors:  Rafik Karaman; Wajd Amly; Laura Scrano; Gennaro Mecca; Sabino A Bufo
Journal:  J Mol Model       Date:  2013-07-09       Impact factor: 1.810

5.  Classification of the crystallization behavior of amorphous active pharmaceutical ingredients in aqueous environments.

Authors:  Bernard Van Eerdenbrugh; Shweta Raina; Yi-Ling Hsieh; Patrick Augustijns; Lynne S Taylor
Journal:  Pharm Res       Date:  2013-11-23       Impact factor: 4.200

6.  Synthesis of a Disulfonated Derivative of Cucurbit[7]uril and Investigations of its Ability to Solubilize Insoluble Drugs.

Authors:  Elizabeth L Robinson; Peter Y Zavalij; Lyle Isaacs
Journal:  Supramol Chem       Date:  2015-05-01       Impact factor: 1.688

Review 7.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

Review 8.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

9.  Ionic liquid versus prodrug strategy to address formulation challenges.

Authors:  Anja Balk; Toni Widmer; Johannes Wiest; Heike Bruhn; Jens-Christoph Rybak; Philipp Matthes; Klaus Müller-Buschbaum; Anastasios Sakalis; Tessa Lühmann; Jörg Berghausen; Ulrike Holzgrabe; Bruno Galli; Lorenz Meinel
Journal:  Pharm Res       Date:  2014-12-23       Impact factor: 4.200

10.  Orally administered DTPA di-ethyl ester for decorporation of (241)Am in dogs: Assessment of safety and efficacy in an inhalation-contamination model.

Authors:  James E Huckle; Matthew P Sadgrove; Erik Pacyniak; Marina G D Leed; Waylon M Weber; Melanie Doyle-Eisele; Raymond A Guilmette; Bushra J Agha; Robert L Susick; Russell J Mumper; Michael Jay
Journal:  Int J Radiat Biol       Date:  2015-05-21       Impact factor: 2.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.